Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07574489 · ClinicalTrials.gov registry record · Phase 2
Whole Versus Partial Gland Boost During Prostate SBRT
A Phase 2 study, sponsored by University of Nebraska.
- Not yet
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT07574489 is a Phase 2 study that has not yet begun recruiting, run by University of Nebraska. The registered enrollment target is 186 participants.
The verdict
NCT07574489, a Phase 2 study, has not yet begun recruiting, sponsored by University of Nebraska.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
Interventions
- RADIATION Prostate stereotactic body radiotherapy with whole gland boost
- RADIATION Prostate stereotactic body radiotherapy with DIL boost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2026-07-25 |
| Est. Completion | 2035-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07574489
The ClinicalTrials.gov registry entry for NCT07574489 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prostate stereotactic body radiotherapy with whole gland boost is the first listed.
NCT07574489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07574489 about?
NCT07574489 is a clinical study titled "Whole Versus Partial Gland Boost During Prostate SBRT". This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
What is the current status of trial NCT07574489?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2026-07-25. Estimated completion is 2035-08-25.
What interventions are being tested in trial NCT07574489?
The interventions under investigation include: Prostate stereotactic body radiotherapy with whole gland boost (RADIATION), Prostate stereotactic body radiotherapy with DIL boost (RADIATION).
Who is sponsoring clinical trial NCT07574489?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.